Navigation Links
Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
Date:7/14/2008

whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able to raise sufficient funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission (the "SEC"), which we strongly urge you to read and consider, including our Registration Statement on Form SB-2, as amended, that was declared effective on July 10, 2006; our annual report on Form 10-KSB filed with the SEC on November 14, 2007; and our Form 10-QSB filed with the SEC on July 9, 2008, all of which are available free of charge on the SEC's web site at http://www.sec.gov. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our reports filed with the SEC. We expressly disclaim any intent or obligation to update any forward-looking statements.

For more information, please contact:

The Ruth Group

Sara Ephraim (investors) Janine McCargo (media)

(646) 536-7002 (646) 536-7033

sephraim@theruthgroup.com jmccargo@theruthgroup.com'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Raptor Pharmaceuticals Closes $10 Million Private Placement
2. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
3. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
4. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
5. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
6. Raptor Pharmaceuticals Acquires Orphan Clinical Program
7. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
8. Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
9. Alexion Pharmaceuticals Invites You to Participate in its Second Quarter 2008 Results Conference Call and Web Cast
10. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
11. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... (PRWEB) August 20, 2014 ... released today including improvements to the enterprise replication ... connectors for Lucene, SOLR and Elasticsearch. This release ... this high performance triplestore – GraphDB™ was formerly ... in deploying the only mature enterprise resilient RDF ...
(Date:8/19/2014)... 19, 2014 Shimadzu Scientific Instruments ... Prominence-i and Nexera-i, adding to the company’s extensive ... functionality, an intuitive operating environment, and full automation, ... efficient workflow for conventional to ultra-high-speed analysis. ... and intelligent design so users can begin building ...
(Date:8/19/2014)... A Geisinger researcher on a personal crusade ... for Disease Control and Prevention (CDC) award recognizing his ... Joseph Boscarino , Ph.D. MPH, senior ... of researchers nominated for the Centers for Disease Control ... Data Methods and Study Design. "Hepatitis C ...
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets  has ... (SOFCs) - Global Strategic Business Report" report to their ... for Solid Oxide Fuel Cells (SOFCs) in US$ Thousands. The ... Canada , Europe , ... forecasts are provided for the period 2012 through 2020. Market ...
Breaking Biology Technology:Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... SAN DIEGO and ST. LOUIS, June 27, 2011 ... industrial biotechnology company focused on the development and commercialization ... manufacturer of animal and human nutrition and health products, ... commercialize a suite of new enzyme products from Verenium,s ...
... of our nation,s long-term clean-energy future, but the technology ... Japan,s recent Fukushima disaster. Indeed, many nations have called ... are operating safely. In the United States, ... percent of the electricity from emission-free sources, including renewable ...
... France, June 24, 2011 Mediabrands, IPG Media ... Lions International Advertising Festival, the results of the ... MIT, Affectiva is able to record and measure ... correlating to an individual,s facial features are established ...
Cached Biology Technology:Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 2Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 3Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 4Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 5Berkeley scientists pioneer nanoscale nuclear materials testing capability 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 3
(Date:8/20/2014)... at Huntsman Cancer Institute (HCI) at the University of ... gene that encodes BCR-ABL, the unregulated enzyme driving the ... American Cancer Society, nearly 6,000 new cases of CML ... use, called tyrosine kinase inhibitors (TKIs), target BCR-ABL and ... cure CML but control it in a way that ...
(Date:8/20/2014)... Using population-based screening outcomes of approximately 3 million ... four researchers at the University of Massachusetts Medical School, ... (SCID) can be successfully implemented across public health newborn ... in the Aug. 20 issue of the Journal ... showed the rate of SCID in newborns is higher ...
(Date:8/20/2014)... sweet and salty aroma of sunscreen and seawater signals ... now reporting that the idyllic beach vacation comes with ... skin and into the sea, they can become toxic ... the main course for many other marine animals. Their ... & Technology . , Antonio Tovar-Sanchez and David Snchez-Quiles ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... is available in German . , ... has developed a model, which identifies potential habitats and corridors ... Rheinland-Pfalz as an example, it was demonstrated that almost half ... enabling a maximum population of 1600 females. The model can ...
... is a link between alcohol consumption and increased risk of ... 5,870 young adult women. The study, published in ... found that the risk increased 3% for every additional alcoholic ... observe any increase in risk of seasonal allergic rhinitis according ...
... Achieves record biometric revenues and profitability, WALL, ... Board: BKYI), a leader in wireless public safety ... profitability and strong revenue growth for its second ... continuing operations for the quarter ended June 30,2008 ...
Cached Biology News:Let the cat keep chasing the mouse 2Let the cat keep chasing the mouse 3Let the cat keep chasing the mouse 4Alcohol is associated with risk of perennial allergic rhinitis 2BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 2BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 3BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 4BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008 5
Mouse polyclonal antibody raised against a partial recombinant LASS3. NCBI Entrez Gene ID = 204219...
... is a sample preparation kit for reduction ... of detergents, phenolic compounds, salts, and most ... samples. The kit procedure involves a TCA-like ... or cells, plant leaves, E. coli, and ...
... Myosin II Heavy Chain Isoform B ... + 0.03% Thimerosal) This antibody was ... to the C-terminus of nonmuscle myosin ... antibody is effective in immunoblotting and ...
MAb to Catenin beta, N-terminal (exon 2) Catenin, beta, N-terminal (exon 2)...
Biology Products: